01—Abstract
Summary
Summary of the 10-Q filed November 4, 2024. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. reported strong revenue growth in the third quarter of 2024, with net revenues reaching $14.46 billiona, a 3.8% increase year-over-year.
This growth was primarily driven by significant increases in sales for key immunology products like Skyrizi and Rinvoq, which saw double-digit percentage increases. The company also experienced positive momentum in its oncology portfolio with the full FDA approval of Elahere and the continued growth of Epkinly and Venclexta. Despite the overall revenue increase, the company faced headwinds with a substantial 37.2%b decrease in Humira sales in the US due to biosimilar competition, a trend expected to continue impacting future results.
The company's strategic acquisitions of ImmunoGen and Cerevel Therapeutics are beginning to integrate, contributing to the overall revenue picture, though also impacting profitability due to amortization of intangible assets and acquisition-related costs. Diluted earnings per share (EPS) for the quarter were $0.88c, a decrease from the prior year's $1.00, largely due to significant amortization of intangible assets and increased operating expenses related to these acquisitions and litigation. Management remains focused on pipeline development and returning cash to shareholders through dividends and share repurchases.
02—Key points
Key Highlights
- Total net revenues increased by 3.8% to $14.46 billion for the three months ended September 30, 2024, compared to $13.93 billion in the prior year period.
- Skyrizi and Rinvoq demonstrated robust growth, with net revenues increasing by 50.8% and 45.3% respectively for the quarter, indicating strong market adoption and execution.
- Humira sales experienced a significant decline of 37.2% in the third quarter due to ongoing biosimilar competition in the US market.
- AbbVie completed the acquisitions of Cerevel Therapeutics (August 1, 2024) and ImmunoGen (February 12, 2024), significantly impacting the balance sheet with increased intangible assets and goodwill, and influencing operating expenses.
- Diluted earnings per share (EPS) decreased to $0.88 from $1.00 year-over-year, primarily impacted by higher amortization of intangible assets and acquisition-related costs.
- The company's R&D expenses increased by 24% to $2.13 billion, reflecting continued investment in its pipeline and innovation across key therapeutic areas.
- AbbVie continues to return capital to shareholders, with cash dividends declared and share repurchases executed during the period.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, AbbVie Inc. kept $0.11.
- Revenue$14.46B100.0%
- Cost of revenue−$4.21B29.1%
- Gross profit$10.25B70.9%
- Operating costs−$6.42B44.4%
- Operating income$3.83B26.5%
- Interest, other & tax−$2.27B15.7%
- Net income$1.56B10.8%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 4, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $14.46B$13.93B | +3.8% |
| Cost of Revenue | $4.21B$6.49B | −35.1% |
| Gross Profit | $10.25B$7.44B | +37.7% |
| SG&A Expenses | $4.21B$3.37B | +24.7% |
| Operating Expenses | $10.63B$11.65B | −8.7% |
| Operating Income | $3.83B$2.28B | +68.0% |
| Interest Expense | $720.00M$555.00M | +29.7% |
| Net Income | $1.56B$1.78B | −12.2% |
| EPS (Basic) | $0.88$1.00 | −12.0% |
| EPS (Diluted) | $0.88$1.00 | −12.0% |
| Shares Outstanding (Basic) | 1.77B1.77B | +0.1% |
| Shares Outstanding (Diluted) | 1.77B1.77B | +0.1% |
05—Questions
Frequently Asked Questions
How did the recent acquisitions of ImmunoGen and Cerevel Therapeutics impact the financial results?
The acquisitions of ImmunoGen and Cerevel Therapeutics, completed in February and August 2024 respectively, significantly impacted the balance sheet with substantial increases in intangible assets and goodwill. These acquisitions also led to higher operating expenses, including amortization of intangible assets and acquisition-related costs, which in turn reduced net earnings and diluted EPS. Revenue from ImmunoGen's products, such as Elahere, began contributing to net revenues post-acquisition.
What is the outlook for Humira sales given the increasing biosimilar competition?
Humira sales continue to decline significantly, down 37.2% year-over-year in the US for the third quarter, due to direct biosimilar competition following loss of exclusivity. This trend is expected to persist, impacting future revenue streams. AbbVie is implementing strategies to maintain formulary access and manage the erosion caused by biosimilars.
How is AbbVie managing its debt and capital structure following the recent acquisitions?
AbbVie financed the ImmunoGen and Cerevel Therapeutics acquisitions through a significant issuance of $15.0 billion in senior notes. The company also utilized a term loan credit agreement. Despite increased debt, AbbVie's balance sheet reflects strategic financial management with continued cash flow generation and an ongoing commitment to returning capital to shareholders through dividends and share repurchases.
What are the key drivers of growth for AbbVie's other major products besides Humira?
Key growth drivers include Skyrizi and Rinvoq, which showed strong double-digit revenue increases, indicating successful market penetration across various immunology indications. Venclexta also demonstrated solid growth in oncology. The company is also seeing positive contributions from newer products like Elahere (post-acquisition) and continued strength in Aesthetics and Neuroscience portfolios (e.g., Botox Cosmetic, Vraylar, Qulipta).
06—Continue